Gabather

0,03 SEK

+8,67 %

Mindre end 1K følgere

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+8,67 %

+5,16 %

-18,50 %

-33,20 %

-69,41 %

-73,96 %

-97,40 %

-97,79 %

-99,23 %

Gabather is a pharmaceutical company whose business focus is to develop drug candidates for the treatment of neurological diseases. The focus is particularly on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Markedsværdi

13,35 mio. SEK

Aktieomsætning

10,31 t SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

15.12

2025

Ekstraordinær generalforsamling '25

26.2

2026

Årsrapport '25

29.5

2026

Delårsrapport Q1'26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Eksterne analyser1.12.2025, 13.57

Gabather: Eager to start the TOTEMS study - VH Corp

* A TOTEMS study article published in Frontiers in Psychiatry * The exercise of TO 7 warrants provides some financial relief * We keep our fair value of SEK 0.092 per share Gabather's reported figures in its recent Q3 report were close to our estimates...

Pressemeddelelse1.12.2025, 13.45

Västra Hamnen Market Focus: Gabather: Eager to start the TOTEMS study

Eksterne analyser1.9.2025, 10.05

Gabather: TOTEMS-study delayed, not derailed - VH Corp

* Issues with clinical test material delays TOTEMS-study * New chairman elected at the AGM * We keep our fair value of SEK 0.092 per share Before releasing its Q2 2025 report, Gabather announced that the TOTEMS-study would be delayed due to issues with...

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse1.9.2025, 10.00

Västra Hamnen Market Focus: Gabather: TOTEMS-study delayed, not derailed

Eksterne analyser19.6.2025, 08.27

Gabather: High potential in specific modulation - VH Corp

• Novel therapeutics addressing the GABAA receptor system in the CNS • An exploratory phase II study in schizophrenia is ongoing • We initiate coverage with a fair value of SEK 0.092 per share Gabather is a drug developer in precision medicine targeting...

Eksterne analyser6.3.2025, 08.55

Gabather: Redefining Cognitive Disorder Treatment - Analyst Group

Gabather AB (“Gabather” or “the Company”) is advancing GT-002, a first-in-class GABAA-modulator, through Phase II clinical trials, targeting cognitive dysfunction. With a fully funded schizophrenia Phase II trial and a planned expansion into Phase II...

Selskabsmeddelelse13.1.2025, 07.30

Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company's share

Selskabsmeddelelse10.4.2024, 11.00

Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

Pressemeddelelse18.3.2024, 07.30

Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Pressemeddelelse7.3.2024, 08.02

Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study

Selskabsmeddelelse22.12.2023, 14.03

Gabather AB receives initial EEG data analysis from the GT-002 target engagement study

Selskabsmeddelelse14.12.2023, 08.16

Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)

Selskabsmeddelelse11.12.2023, 12.23

Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG

Selskabsmeddelelse12.10.2023, 12.00

Gabather AB: Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers

Selskabsmeddelelse13.4.2023, 06.45

Gabather AB: Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957

Selskabsmeddelelse7.6.2022, 08.57

Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1

Pressemeddelelse2.6.2022, 08.00

Gabather AB: BioStock: Gabather's lead candidate moves forward in the clinic

Selskabsmeddelelse17.5.2022, 13.36

Gabather AB: Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002

Selskabsmeddelelse22.3.2022, 08.00

Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Selskabsmeddelelse14.9.2021, 06.37

Gabather AB: BioStock: Gabather poised to complete phase I with GT-002

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.